LYMPHOCYTE ACTIVATION GENE - 3 PROTEIN MARKET ANALYSIS

Lymphocyte Activation Gene - 3 Protein Market, by Drug (BMS-986016 (Relatlimab), IMP321, IMP701, MGD013, and Others), by Cancer Type (Breast Cancer, Melanoma, Solid Tumors, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Nov 2024
Code : CMI2027
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Lymphocyte Activation Gene - 3 Protein Market Regional Insights

North America is expected to witness significant growth in the LAG -3 protein market over the forecast period. Robust pipeline of LAG-3 protein antibodies and the increasing demand for such drugs is expected to facilitate growth of the market, in the U.S. For instance, Bristol-Myers Squibb has Relatlimab in phase II clinical trials and Regeneron Pharmaceuticals Inc., in collaboration with Sanofi, has REGN3767 in phase I clinical trials, 2017.

High prevalence of various types of cancer in North America, Europe, and Asia Pacific region is expected to be a major factor contributing growth of the lymphocyte activation gene - 3 protein market over the forecast period. According to European Union (EU), in 2014, almost 1/3^rd million people died from cancer in the EU-28. Moreover, manufacturers are focused on conducting clinical trials in these regions to expand their potential customer base.

Geographies covered